Tema Etfs LLC Acquires Shares of 16,066 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Tema Etfs LLC bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,066 shares of the company's stock, valued at approximately $413,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Barclays PLC increased its stake in shares of IDEAYA Biosciences by 188.8% in the third quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after buying an additional 118,438 shares during the period. JPMorgan Chase & Co. grew its holdings in IDEAYA Biosciences by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock worth $2,527,000 after acquiring an additional 12,029 shares during the last quarter. SG Americas Securities LLC increased its position in IDEAYA Biosciences by 444.2% in the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock valued at $475,000 after acquiring an additional 15,089 shares during the period. KBC Group NV raised its stake in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after acquiring an additional 1,923 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of IDEAYA Biosciences during the fourth quarter valued at $35,000. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA traded up $0.14 during midday trading on Friday, reaching $18.82. The stock had a trading volume of 1,046,582 shares, compared to its average volume of 1,003,193. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -5.70 and a beta of 0.26. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The company's 50 day moving average price is $17.65 and its 200 day moving average price is $21.86.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the business posted ($0.53) EPS. Equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on IDYA shares. Stephens restated an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $54.27.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.